342 assets in Glioblastoma

Therapeutic assets addressing Glioblastoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Microbubble Glioblastoma	NaviFUS Corporation	P3	B (57)
Temsirolimus Glioblastoma	Nader Sanai	P2	B (57)
Abemaciclib Glioblastoma	Tango Therapeutics, Inc.	P2	B (56)
AXUMIN Glioblastoma	Abramson Cancer Center at Penn Medicine	P2	B (56)
Cetuximab Glioblastoma	University of Miami	P2	B (56)
Dabrafenib Glioblastoma	National Cancer Institute (NCI)	P4	B (56)
Fibromun Glioblastoma	Philogen S.p.A.	P2	B (56)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Glioblastoma	National Cancer Institute (NCI)	P2	B (56)
Olaparib Glioblastoma	Fundación de investigación HM	P2	B (56)
Palbociclib Glioblastoma	AHS Cancer Control Alberta	P2	B (56)
Pazopanib Glioblastoma	Center Trials & Treatment	P2	B (56)
Ribociclib Glioblastoma	Nationwide Children's Hospital	P2	B (56)
Selinexor Glioblastoma	National Cancer Institute (NCI)	P2	B (56)
Catequentinib Glioblastoma	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P2	CCC (55)
Fludeoxyglucose Glioblastoma	Jonsson Comprehensive Cancer Center	P2	CCC (55)
Gliolan Glioblastoma	Universität Münster	P2	CCC (55)
Human Cmv Pp65-Lamp Mrna-Pulsed Autologous Dcs Glioblastoma	Annick Desjardins, MD	P2	CCC (55)
Sargramostim Glioblastoma	Children's Oncology Group	P2	CCC (55)
Survaxm Glioblastoma	Children's Oncology Group	P2	CCC (55)
Tislelizumab Glioblastoma	Jiangsu Healthy Life Innovation Medical Technology Co., Ltd	P2	CCC (55)
Autologous Monocytes Glioblastoma	Aivita Biomedical, Inc.	P3	CCC (54)
FDOPA Glioblastoma	Mayo Clinic	P2	CCC (54)
Montanide Isa 51 Glioblastoma	Children's Oncology Group	P2	CCC (54)
o6-benzylguanine Glioblastoma	Leland Metheny	P2	CCC (54)
Pamiparib Glioblastoma	Nader Sanai	P1/2	CCC (54)
Pegargiminase Glioblastoma	Sabine Mueller, MD, PhD	P2/3	CCC (54)
Retifanlimab Glioblastoma	Academic and Community Cancer Research United	P2	CCC (54)
Tofacitinib Glioblastoma	University of Texas Southwestern Medical Center	P3	CCC (54)
Troriluzole Glioblastoma	Ugonma Chukwueke	P2/3	CCC (54)
Vebreltinib Glioblastoma	Huashan Hospital	P2/3	CCC (54)
AK105 Glioblastoma	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P2	CCC (53)
Balstilimab Glioblastoma	Northwestern University	P2	CCC (53)
Bl-B01D1 For Glioblastoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (53)
Botensilimab Glioblastoma	Northwestern University	P2	CCC (53)
Chlorophyllin Copper Complex Sodium Glioblastoma	Tata Memorial Centre	P2	CCC (53)
doc1021 Glioblastoma	Diakonos Oncology Corporation	P2	CCC (53)
Eukystol Glioblastoma	Southern Medical University, China	P2	CCC (53)
g207 Glioblastoma	Pediatric Brain Tumor Consortium	P2	CCC (53)
gi-102 Glioblastoma	Mayo Clinic	P2	CCC (53)
Glucose, Anhydrous Glioblastoma	Stanford University	P2	CCC (53)
Gsc-Dcv Glioblastoma	Huashan Hospital	P2	CCC (53)
jk-1201i Glioblastoma	JenKem Technology Co., Ltd.	P2	CCC (53)
kh617 Glioblastoma	Sichuan Honghe Biotechnology Co., Ltd.	P2	CCC (53)
Liothyronine Glioblastoma	Emory University	P2	CCC (53)
Nano2Tm Glioblastoma	NuvOx LLC	P2	CCC (53)
Olutasidenib Glioblastoma	Rigel Pharmaceuticals	P2	CCC (53)
p140k-mgmt Glioblastoma	Leland Metheny	P2	CCC (53)
Pumitamig Glioblastoma	BioNTech SE	P2	CCC (53)
Romiplostim Glioblastoma	European Organisation for Research and Treatment of Cancer - EORTC	P2	CCC (53)
Thiotepa Glioblastoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CCC (53)

Showing 51 to 100 of 342 assets

PreviousPage 2 of 7Next